Norma C. Gutiérrez

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

Laura Rosiñol, Albert Oriol, Ana Isabel Teruel et al. · Blood · 2012 · 485 citations · Full text

Medicine, Hematology, Pharmacology +14

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

Bruno Paiva, María‐Belén Vídriales, Jorge Cerveró et al. · Blood · 2008 · 475 citations · Full text

Medicine, Hematology, Immunology +17

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

María‐Victoria Mateos, Albert Oriol, Joaquín Martínez‐López et al. · The Lancet Oncology · 2010 · 459 citations · Full text

Medicine, Hematology, Pharmacology +17

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

María‐Victoria Mateos, JoséM. Hernández, M.B. Gómez Hernández et al. · Blood · 2006 · 389 citations · Full text

Medicine, Hematology, Oncology +15

Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification

Jesús F. San Miguel, María‐Belén Vídriales, C López-Berges et al. · Blood · 2001 · 332 citations · Full text

Medicine, Hematology, Oncology +16